Ionis Pharmaceuticals IONS Available-for-Sale Debt Securities - Amortized Cost
Available-for-Sale Debt Securities - Amortized Cost at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's available-for-sale debt securities - amortized cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's available-for-sale debt securities - amortized cost?
- Ionis Pharmaceuticals (IONS) reported available-for-sale debt securities - amortized cost of $1.75B in Q1 2026.
- How has Ionis Pharmaceuticals's available-for-sale debt securities - amortized cost changed year-over-year?
- Ionis Pharmaceuticals's available-for-sale debt securities - amortized cost decreased by 8.6% year-over-year, from $1.91B to $1.75B.
- What is the long-term trend for Ionis Pharmaceuticals's available-for-sale debt securities - amortized cost?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's available-for-sale debt securities - amortized cost has grown at a 17.1% compound annual growth rate (CAGR), from $1.25B to $2.35B.
- What does available-for-sale debt securities - amortized cost mean?
- The original purchase price of debt investments adjusted for accounting adjustments over time.
- How do you interpret available-for-sale debt securities - amortized cost?
- An increase suggests the company is deploying more cash into fixed-income instruments, while a decrease indicates a reduction in the size of the debt investment portfolio.
- How does available-for-sale debt securities - amortized cost compare across companies?
- Standard for biotech firms with significant cash reserves held in conservative investment vehicles.